FibroBiologics to Present at Bio-Europe 2025

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at Bio-Europe 2025 in Vienna, Austria, on November 4, 2025 at 4:15 p.m. CET.

The company said it will be available for one-on-one investor meetings during the conference (November 3–5, 2025) and that additional information is available via the company website or email at info@fibrobiologics.com. FibroBiologics focuses on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending.

News Market Reaction

+6.28%

2 alerts

+6.28% News Effect

+$1M Valuation Impact

$19M Market Cap

0.9x Rel. Volume

On the day this news was published, FBLG gained 6.28%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $19M at that time.

Data tracked by StockTitan Argus on the day of publication.

HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Bio-Europe 2025 conference taking place November 3-5, 2025, at the Vienna Congress and Convention Center in Vienna, Austria.

FibroBiologics will deliver a company presentation at 4:15 p.m. CET on Tuesday, November 4, and will be available for one-on-one investor meetings throughout the event.

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

When will FibroBiologics (FBLG) present at Bio-Europe 2025?

FibroBiologics will present on November 4, 2025 at 4:15 p.m. CET.

Where is the Bio-Europe 2025 presentation by FibroBiologics (FBLG) taking place?

The presentation is at the Vienna Congress and Convention Center in Vienna, Austria.

Who from FibroBiologics (FBLG) will present at Bio-Europe 2025?

Founder and Chief Executive Officer Pete O’Heeron will deliver the company presentation.

Can investors meet FibroBiologics (FBLG) executives at Bio-Europe 2025?

Yes. The company will be available for one-on-one investor meetings throughout the event (November 3–5, 2025).

How can I get more information about FibroBiologics (FBLG) at Bio-Europe 2025?

Visit the company website or email info@fibrobiologics.com for details and meeting requests.

What is FibroBiologics’ (FBLG) area of focus mentioned for the Bio-Europe 2025 presentation?

The company focuses on developing therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending.